Navigation Links
ForteBio Announces Launch of Protein G Biosensor for Use on Company's Octet® Instruments
Date:9/3/2010

MENLO PARK, Calif., Sept. 3 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency. The company also announced that it has completed International Standards Organization (ISO) certification of its biosensor manufacturing facility.

"Protein G uniquely binds to many mammalian IgGs, such as murine, goat, bovine and other IgGs, making it an important tool in antibody discovery, cell line development and production monitoring," said Christopher Silva, ForteBio's vice president of marketing. "Traditional IgG quantification methods for numerous species and subtypes using Protein G, however, are complicated, labor-intensive and time-consuming. Now, with ForteBio's new Protein G biosensor, researchers can obtain highly specific binding information in real time, in a cost-effective and easy-to-use manner." Mr. Silva also noted that the company's Protein G biosensor can be regenerated and reused, for increased workflow flexibility and cost-efficiency.

The new biosensor comes with recombinant Protein G pre-immobilized on the surface and is ready to use on ForteBio's Octet instruments. ForteBio's Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

To date over 2.5 million biosensor assays have been run on Octet systems, a testament to the high reproducibility, accuracy and robustness of the platform.

The company also announced that its biosensor manufacturing facility is now ISO 9001:2008-certified, underscoring the quality of its products.

ABOUT FORTEBIO, INC.ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com. Contact: Gemma Milan650-289-6800gmilan@fortebio.com
'/>"/>

SOURCE ForteBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
2. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
3. Nutraceutical Leader Announces Internal Promotions of Key Personnel
4. United American Healthcare Corporation Announces Increase in Board Size and New Director Nominees
5. Ellman International Announces Executive Team Hire
6. Yongye International Announces RMB 400 Million Revolving Credit Facilities
7. QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
8. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
9. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
10. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
11. Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech Fund ...
(Date:5/3/2016)... Ore. , May 3, 2016   BIOTRONIK ... importance of extending care beyond the implant at the ... May 4-7 in San Francisco . ... continually delivering the highest quality of patient care and ... are cared for each and every tomorrow," said ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER ... and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all ... May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Nike Rugby ... junior rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike ... and players every year since 2009. , “I’m excited for our eighth summer ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... a master charity program created to assist the people of their local community. ... with nonprofit organizations and community leaders. Their hope is to bring awareness to ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... surgery at their office. Wisdom tooth removal, a common dental procedure, is performed for ... often are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental business ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and driving ... her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in both ...
Breaking Medicine News(10 mins):